Icosapent Ethyl
Brand name: Vascepa
Rank #54 of 500 drugs by total cost
$334.9M
Total Cost
692,252
Total Claims
$334.9M
Total Cost
16,235
Prescribers
$484
Cost per Claim
96,633
Beneficiaries
1,083,935
30-Day Fills
$21K
Avg Cost/Provider
43
Avg Claims/Provider
About Icosapent Ethyl
Icosapent Ethyl (sold as Vascepa) was prescribed 692,252 times by 16,235 Medicare Part D providers in 2023, costing the program $334.9M. At $484 per claim, this is a moderately priced medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 51 | Secukinumab (Cosentyx Sensoready (2 Pens)) | $347.7M | 45,496 |
| 52 | Upadacitinib (Rinvoq) | $346.0M | 51,469 |
| 53 | Abiraterone Acetate (Abiraterone Acetate) | $345.0M | 122,643 |
| 54 | Icosapent Ethyl (Vascepa) | $334.9M | 692,252 |
| 55 | Cariprazine Hcl (Vraylar) | $329.1M | 226,854 |
| 56 | Albuterol Sulfate (Albuterol Sulfate Hfa) | $312.2M | 7,904,120 |
| 57 | Rifaximin (Xifaxan) | $310.0M | 111,328 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology